High materiality9/10
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Silexion's SLXN stock rose 21.72% after Phase 2 trial results. LODER demonstrated a 56% objective response rate in patients. Patients with resectable tumors saw ORR increase to 67%. Overall survival improved by 9.3 months with LODER and chemotherapy. Silexion is developing SIL-204, targeting broader KRAS mutations.
- Silexion's SLXN stock rose 21.72% after Phase 2 trial results.
- LODER demonstrated a 56% objective response rate in patients.
- Patients with resectable tumors saw ORR increase to 67%.
- Overall survival improved by 9.3 months with LODER and chemotherapy.
- Silexion is developing SIL-204, targeting broader KRAS mutations.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.